Skip to main content
OpenTrials
Completed

NCT Number: NCT00508027

Simvastatin (Zocor) Therapy in Sickle Cell Disease

Recent clinical and experimental data indicate that statins have effects beyond cholesterol lowering that may be beneficial in sickle cell disease by protecting the vascular endothelium. Statins have been shown to attenuate endothelial dysfunction through their anti-inflammatory, anti-oxidant and anti-thrombotic properties. This phase I/II dose-escalating trial is designed to assess the safety and potential clinical efficacy of oral simvastatin (Zocor)in adolescents and adults with sickle cell disease (SCD).

Completed

Looking for future studies?

Notify Me

Key information

Age range

13 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Children's Hospital and Research Center Oakland

Oakland, California, 94609, United States

About this study

Although statins have been used extensively for their cholesterol-lowering effects, recent clinical and experimental data indicate that statins regulate yet other processes, many of which play a major role in sickle cell disease (SCD). Independent of their cholesterol-lowering effects, statins have been shown to prevent damage to blood vessels in several ways, through upregulation of endothelial nitric oxide (NO)and decreased inflammation. Numerous studies documenting the protective effects of statins, together with data showing the therapeutic role of NO in SCD, provide the basis for investigating the potential clinical benefit of simvastatin in SCD.

Data supporting the safety and tolerability of simvastatin in patients with SCD are now needed. For this phase I/II dose-escalation study of oral simvastatin in SCD, we propose the following specific aims:

  • To obtain preliminary efficacy data on the effects of oral simvastatin on plasma biomarkers of endothelial injury in patients with SCD, and
  • To assess the safety and tolerability of oral simvastatin in patients with SCD.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Established diagnosis of sickle cell disease (HbSS, SC or Sβ-thalassemia)
  • Age greater than or equal to thirteen years
  • Weight greater than or equal to 35 kg

Exclusion criteria

  • Renal dysfunction (Serum Creatinine > 1.5 UNL)
  • Hepatic dysfunction (ALT > 2X UNL)
  • Pretreatment total cholesterol < 100 mg/dL or triglycerides < 30 mg/dL
  • Pretreatment baseline creatine kinase >1X UNL (215 U/L)
  • Pregnancy/lactation
  • RBC transfusion in the last 30 days
  • Vaso-Occlusive Event needing hospitalization in the past 30 days
  • Treatment with any statin drugs within the past 30 days
  • Treatment with drugs having known metabolic interactions with statin drugs (e.g. cytochrome P450 3A4 metabolism), including ketoconazole, itraconazole, fluconazole, erythromycin, clarithromycin, azithromycin, niacin (nicotinic acid), digoxin, coumadin, sildenafil or amiodarone within the past 30 days
  • Treatment (past or present) with amiodarone
  • Musculoskeletal disorder associated with an elevated creatine kinase level
  • Past or present history of substance abuse (alcohol, cocaine, amphetamines, heroin, PCP)
  • Allergy to statins

Treatment and study plan

simvastatin

Drug

Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.

Other names: Zocor

Primary outcomes

  1. Change in Total Cholesterol Level

    Time frame: Baseline, 21 days

    Change in serum total cholesterol level after treatment with simvastatin

  2. Change in Hemoglobin Level

    Time frame: Baseline, 21 days

    Change in plasma hemoglobin (Hb) level after treatment with simvastatin

  3. Change in Serum Creatine Kinase Levels

    Time frame: Baseline, 21 days

    Change in serum creatine kinase (CK) levels after treatment with simvastatin

  4. Change in Serum Alanine Transaminase (ALT) Levels

    Time frame: Baseline, 21 days

    Change in serum alanine transaminase (ALT) after treatment with simvastatin

  5. Change in Serum Creatinine Levels

    Time frame: Baseline, 21 days

    Change in serum creatinine (Cr) levels after treatment with simvastatin

Other outcomes

  1. Change in Plasma NOx Levels

    Time frame: Baseline, 21 days

    Measurements of the levels of plasma nitric oxide metabolites (NOx), high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), vascular cell adhesion molecule-1 (VCAM-1), tissue factor (TF) and vascular endothelial growth factor (VEGF)were performed before and after simvastatin treatment. Changes in mean plasma biomarker levels were assessed for each dose level; however, dose level 3 results were not analyzed, as only 2 subjects were enrolled in this dose group.

  2. Change in Plasma Hs-CRP Levels

    Time frame: Baseline, 21 days

    Change in plasma high sensitivity C-reactive protein levels in subjects treated with simvastatin

  3. Change in Plasma IL-6 Levels

    Time frame: Baseline, 21 days

    Change in plasma IL-6 level after treatment with simvastatin

  4. Change in Plasma VEGF Levels

    Time frame: Baseline, 21 days

    Change in plasma vascular endothelial adhesion molecule-1 levels after treatment with simvastatin

  5. Change in Plasma VCAM1 Levels

    Time frame: Baseline, 21 days

    Change in plasma vascular cellular adhesion molecule-1 levels after treatment with simvastatin

  6. Change in Plasma TF Levels

    Time frame: Baseline, 21 days

    Change in plasma tissue factor (TF) levels after treatment with simvastatin

Sponsors and collaborators

Lead sponsor

UCSF Benioff Children's Hospital Oakland

Other

Collaborators

  • Department of Health and Human Services
  • FDA Office of Orphan Products Development

Registry information

Official study title

Phase I/II Study of Simvastatin (Zocor) Therapy in Sickle Cell Disease

Important dates

Study start
2007
Primary completion
2011
Study completion
2011
First posted
Jul 27, 2007
Registry last updated
Sep 17, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.